---
layout: post
title: "Investigator Responsibilities-Safety Reporting for Investigational Drugs and Devices; Guidance for Investigators, Industry, and Institutional Review Boards; Availability"
date: 2026-02-04 21:37:07 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-22869
original_published: 2025-12-16 00:00:00 +0000
significance: 8.00
---

# Investigator Responsibilities-Safety Reporting for Investigational Drugs and Devices; Guidance for Investigators, Industry, and Institutional Review Boards; Availability

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 16, 2025 00:00 UTC
**Document Number:** 2025-22869

## Summary

The Food and Drug Administration (FDA or the Agency) is announcing the availability of a final guidance for investigators, industry, and institutional review boards (IRBs) entitled "Investigator Responsibilities--Safety Reporting for Investigational Drugs and Devices." The guidance is intended to help clinical investigators comply with the safety reporting requirements for investigational new drug application (IND) studies and investigational device exemption (IDE) studies. As such, recommendations are provided in this guidance to help investigators identify safety information that needs to be reported to sponsors and IRBs. This guidance finalizes the draft guidance of the same title issued on September 30, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/16/2025-22869/investigator-responsibilities-safety-reporting-for-investigational-drugs-and-devices-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2025-22869

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
